Inogen appoints former ZimVie CEO Vafa Jamali to board as independent director

Inogen, Inc. +5.24%

Inogen, Inc.

INGN

6.53

+5.24%

  • Inogen appointed Vafa Jamali as independent director, effective on date of 2026 annual meeting or June 15 if earlier.
  • Jamali previously served as CEO of ZimVie, leading its Nasdaq listing following spin-out from Zimmer Biomet.
  • He also held senior roles at Medtronic, most recently as senior vice president and president of Respiratory, Gastrointestinal & Informatics, a $3 billion division.
  • Inogen entered cooperation agreement with shareholder Kent Lake tied to Jamali’s board appointment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inogen Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604061600BIZWIRE_USPR_____20260406_BW176231) on April 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.